Fixed-dose combination tablets with dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter-2 inhibitor for type 2 diabetes adjunctive therapy. Pharmaceutical manufacturers supply to wholesalers, hospitals, and pharmacies for procurement by endocrinologists and primary care facilities in diabetes management programs.